Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Dispenzieri, Angela  [Clear All Filters]
2013
Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, et al. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2013.
2014
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med. 2014;371(10):906-917.
Sharma M, Zhang M-J, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, et al. Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biol Blood Marrow Transplant. 2014.
Dispenzieri A. POEMS syndrome: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(2):213-23.
Chandrashekaran S, Dispenzieri A, Cha SS, Kennedy CC. Pulmonary morbidity improves after autologous stem cell transplantation in POEMS syndrome. Respir Med. 2014.
2015
Cordes S, Gertz MA, Buadi FK, Lin Y, Lacy MQ, Kapoor P, Kumar SK, McCurdy A, Dispenzieri A, Dingli D, et al. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagul Fibrinolysis. 2015.
Mir MA, Kapoor P, Kumar S, Pandey S, Dispenzieri A, Lacy MQ, Dingli D, Hogan W, Buadi F, Hayman S, et al. Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clin Lymphoma Myeloma Leuk. 2015.
2016
Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematol. 2016;135(3):172-190.
Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016.
Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, S Rajkumar V, Go RS, Leung N, et al. Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation. Am J Hematol. 2016.
Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016.
2018
M Sidiqi H, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, et al. Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant. 2018.
M Sidiqi H, Aljama M, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, et al. Prognostic significance of stringent complete response post stem cell transplantation in AL amyloidosis. Biol Blood Marrow Transplant. 2018.
2019
Sidana S, M Sidiqi H, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, et al. 15 Year Overall Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis. Am J Hematol. 2019.
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, et al. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019.
2020
Saleh ASAl, M Sidiqi H, Lee J, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, et al. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplant. 2020.
Moreira CL, M Sidiqi H, Buadi FK, Litzow MR, Gertz MA, Dispenzieri A, Russell SJ, Ansell SM, Stegall MD, Prieto M, et al. Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation. 2020.
Saleh ASAl, M Sidiqi H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kourelis TV, et al. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Saleh ASAl, Parmar HV, Vaxman I, Visram A, M Sidiqi H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, et al. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2020.
Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79-89.
2021
Wudhikarn K, Padrnos L, Lasho T, LaPlant B, Kumar S, Dispenzieri A, Lacy M, Rajkumar SV, Gertz M, Mangaonkar AA, et al. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. Am J Hematol. 2021.
Vaxman I, Muchtar E, Jacob E, Prashant K, Kumar S, Dispenzieri A, Buadi F, Dingli D, Gonsalves W, Kourelis T, et al. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients That Are "Poor Responder" to Induction- The Mayo Clinic Experience. Transplant Cell Ther. 2021.
Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, et al. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021;5(13):2753-2759.
Vaxman J, Dispenzieri A. The Role of Autologous Stem Cell Transplantation in Amyloidosis. Oncology (Williston Park). 2021;35(8):471-478.
2022
Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, et al. Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplant Cell Ther. 2022.

Pages